← SynDRA
Nrc-2694
SynDRA canonical compound SYN0061415 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | anticancer agent |
|---|
| Indication | non-small cell lung cancer (nsclc) |
|---|
| Disease area | oncology |
|---|
Cross-references
Synonyms
- UNII-O898S9836V
- RefChem:166910
- EGFR Inhibitor NRC-2694
- NRC2694
- O898S9836V
- WBKHQQZRHCECKK-UHFFFAOYSA-N
- SCHEMBL828788
- orb1307951
- SCHEMBL29483201
- C24H26N4O3
- LMB44661
- BDBM50455959
- MFCD30532745
- NRC-2694?
- AKOS040742312
- CS-6754
- AC-36681
- HY-19909
- MS-27321
- DB-209593
- G15936
- T16343
- orb1738148
- 6RZ8T2FCG6
- UNII-6RZ8T2FCG6
- NRC-2694A
- HY-19909A
- NRC-2694 hydrochloride
- NRC-2694-A
- NRC-2694B
- JRT6MBD7C2
- NRC-2694 dihydrochloride
- SCHEMBL30133464
- orb1738149
- UNII-JRT6MBD7C2
- SCHEMBL20534441
Look up Nrc-2694 in the interactive SynDRA portal →